37.
http://www.ahcpub.com/ahc_root_html/hot/sponsored/cox-
2_table2.html. 14.8.2007 tarihinde eriflilmifltir.
38.
Bjorkman DJ. One hundred years of NSAID gastropathy:
are coxibs the answer? Rev Gastroenterol Disord
2001;1:121-7.
39.
Lanes SF, Garcia Rodriguez LA, HwangG E. Baseline risk of
gastrointestinal disorders among new users of meloxicam,
ibuprofen, diclofenac, naproxen and indomethacin. Pharma-
coepidemiology and Drug Safety 2000;9:113-7.
40.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R,
Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M.
Adenoma Prevention with Celecoxib (APC) Study Investi-
gators.Cardiovascular Risk Associated with Celecoxib in a
Clinical Trial for Colorectal Adenoma Prevention. N Engl J
Med 2005;352(11):1071-80.
41.
Solomon DH. NSAIDs: Mechanism of action. UpToDate
online version 15.2.
42.
Smith WL, De Witt DL, Garavito RM. Cyclooxygenases:
structural, cellular and molecular biology. Ann Rev Bioc-
hem 2000;69:145-82.
43.
Crofford LJ. Prostaglandin biology. Gastroenterol Clin
North Am 2001;30:863-76.
44.
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Ste-
geman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning
TD, Seibert K, Isakson PC, Stallings WC. Structural basis
for selective inhibition of cyclooxygenase-2 by anti-inflam-
matory agents. Nature 1996;384:644-8.
45.
Crofford LJ. Nonsteroidal Antiinflammatory Drugs. In:
Harris ED, Jr Budd RC, Firestein GS, Genovese MC, Ser-
gent JS, Ruddy S, Sledge BC (Eds). Kelley's Textbook of
Rheumatology (7th ed.), Elsevier Science, Philadelphia,
2005; pp. 839-58.
46.
Kayaalp S. T>bbi Farmakoloji. Ankara: Hacettepe Tafl,
2002.
47.
Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS,
van de Putte LB. Basic biology and clinical application of
specific cyclooxygenase-2 inhibitors. Arthritis Rheum
2000;43:4-13.
48.
Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA,
Prescott SM. Dixon DA, Kaplan CD, McIntyre TM, Zim-
merman GA, Prescott SM. Post-transcriptional control of
cyclooxygenase-2 gene expression. The role of the 3'-un-
translated region. J Biol Chem 2000;275:11750-7.
49.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon
LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology
and disease. Faseb J 1998;12:1063-73.
50.
Brater DC. Renal effects of cyclooxygyenase-2-selective in-
hibitors. J Pain Symptom Manage 2002;23: S15-20; discus-
sion S21-13.
51.
Fitzgerald GA. The choreography of cyclooxygenases in the
kidney. J Clin Invest 2002;110:33-4.
52.
Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygena-
se 2 function is essential for bone fracture healing. J Bone
Miner Res 2002;17:963-76.
53.
Vane JR, Botting RM. Mechanism of action of anti-inflam-
matory drugs. Adv Exp Med Biol 1997;433:131-8.
54.
FitzGerald GA. The choreography of cyclooxygenases in the
kidney. J Clin Invest 2002;110:33-4.
55.
Hochberg MC. New directions in symptomatic therapy for
patients with osteoarthritis and rheumatoid arthritis. Semin
Arthritis Rheum 2002;32:4-14.
56.
Emmerson BT. The management of gout. N Engl J Med
1996;334:445-51.
57.
Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral
roles of prostaglandins in pain and their interactions with
novel neuropeptides nociceptin and nocistatin. Neuroscien-
ce Res 2001;41:299.
58.
Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD,
Isakson PC. The acute antihyperalgesic action of nonsteroi-
dal, anti-inflammatory drugs and release of spinal prost-
glandin E2 is mediated by inhibition of constitutive spinal
cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci
2001;21:5847-53.
59.
Santana-Sahagun E, Weisman MH. Nonsteroidal anti-inf-
lammatory drugs. In: Ruddy S,Harris ED, Sledge CB (Eds).
Kelley's Textbook of Rheumatology. W.B. Saunders Com-
pany. Philadelphia, 2001; pp. 799-822.
60.
Antithrombotic Trialists' Collaboration: Collaborative me-
taanalsis of randomised trials of antiplatelet therapy for pre-
vention of death, myocardial infarction, and stroke in high
risk patients. British Med J 2002;324:71.
61.
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for
the primary prevention of cardiovascular events: a summary
of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med 2002;136:161-72.
62.
Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ,
DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclo-
oxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med 2001;345:1809-17.
63.
Kawai N, Tsujii M, Tsuji S. Cyclooxygenases and colon can-
cer. Prostaglandins Other Lipid Mediat 2002;68-69:187-
96.
64.
Giardeillo FM, Offerhaus GJA, DuBios RN. The role of
nonsteroidal antiinflammatory drugs in colorectal cancer
prevention. Eur J Cancer 1995;31A:1071.
65.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bre-
salier R, McKeown-Eyssen G, Summers RW, Rothstein R,
Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck
GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon
N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomi-
zed trial of aspirin to prevent colorectal adenomas. N Engl
J Med 2003;348:891-9.
66.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Ke-
resztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Ste-
inbach G, Schilsky R.. A randomized trial of aspirin to pre-
vent colorectal adenomas in patients with previous colorec-
tal cancer. N Engl J Med 2003;348:883-90.
KISIM 4
n
T>bbi Rehabilitasyonda Tedavi Yaklafl>mlar>
798